Mirum Pharmaceuticals, Inc. (MIRM) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
Despite a 25% YoY revenue increase, the net loss and rising R&D expenses offset positive momentum. The absence of strategic initiatives or risk discussion suggests uncertainty. The market cap indicates moderate sensitivity, justifying a neutral prediction.
Key Financial Performance
Revenue Mirum Pharmaceuticals reported a revenue of $75 million for Q1 2026, representing a 25% increase year-over-year. This growth was driven by strong sales of their lead product, Livmarli, and expansion into new markets.
Net Loss The company reported a net loss of $10 million for Q1 2026, which is an improvement from the $15 million net loss in Q1 2025. The reduction in net loss was attributed to increased revenue and cost management initiatives.
Research and Development Expenses R&D expenses were $20 million in Q1 2026, up 10% year-over-year. The increase was due to ongoing clinical trials and investment in pipeline development.
Selling, General, and Administrative Expenses SG&A expenses were $30 million in Q1 2026, a 5% increase compared to Q1 2025. This was primarily due to higher marketing costs associated with the launch of new products.
Cash and Cash Equivalents The company ended Q1 2026 with $200 million in cash and cash equivalents, down from $220 million at the end of Q1 2025. The decrease was due to investments in R&D and commercialization efforts.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Bhasin Morgan
Brian Skorney
Co Research
Cowen Research
Director Peter
Division Brian
Division Condulis
Division Fye
Division PM
Division Rohit
Division Ryan
Division Schimmer
Division Thome
Division Wallace
Division Walter
EDT afternoon
Eric Bjerkholt
Fye JPMorgan
Incorporated Research
Joanne Quan
Jonathan Wolleben
LLC Research
Officer Joanne
Officer Yesha
PM EDT
Patel Evercore
Peter Radovich
President Eric
Radovich COO
Research Division
Rohit Bhasin
Ryan Deschner
Ryan Mcelroy
MIRM Transcript
Mirum Pharmaceuticals, Inc. (MIRM) Q1 2026 Earnings Call Transcript
Unknown5-6
Despite a 25% YoY revenue increase, the net loss and rising R&D expenses offset positive momentum. The absence of strategic initiatives or risk discussion suggests uncertainty. The market cap indicates moderate sensitivity, justifying a neutral prediction.
Mirum Pharmaceuticals, Inc. (MIRM) Q4 2025 Earnings Call Transcript
Positive2-25
The earnings call summary reflects strong financial performance with 55% YoY sales growth and improved cash position. Product development is promising, with milestones and international expansion underway. The Q&A section addressed potential risks effectively, showing management's confidence in overcoming challenges. Despite operational risks, the positive financial metrics and optimistic guidance suggest a potential stock price increase. The market cap indicates a moderate reaction is likely, so a 'Positive' sentiment is justified.
Mirum Pharmaceuticals, Inc. (MIRM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-14
Mirum Pharmaceuticals, Inc. (MIRM) Presents at Evercore 8th Annual Healthcare Conference Transcript
Neutral12-2
MIRM Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
